Format

Send to

Choose Destination
J Neuroimmunol. 2013 Jan 15;254(1-2):28-38. doi: 10.1016/j.jneuroim.2012.08.013. Epub 2012 Sep 23.

Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis.

Author information

1
Department of Neurology, Thomas Jefferson University, 300 JHN Building, 900 Walnut Street, Philadelphia, PA 19107, United States.

Abstract

Zymosan has previously been reported to have both pro-inflammatory and anti-inflammatory effects. Here we demonstrate that low dose zymosan prevented or reversed chronic and relapsing paralysis in EAE. In suppressing CNS autoimmune inflammation, zymosan not only regulated APC costimulator and MHC class II expression, but also promoted differentiation of regulatory T cells. Following adoptive transfer of zymosan-primed CD4(+) T cells, recipient mice were protected from EAE. In contrast, a MAPK inhibitor and a blocker of β-glucan, reversed the effects of zymosan. These results demonstrate that zymosan may be a promising beneficial agent for Multiple Sclerosis (MS).

PMID:
23010280
PMCID:
PMC3534935
DOI:
10.1016/j.jneuroim.2012.08.013
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center